Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
European Journal of Gynaecological Oncology|December 5, 2006
Do risk factors for epithelial ovarian cancer have an impact on prognosis? Focus on previous pelvic surgery and reproductive variablesA Kjaerbye-Thygesen, K Frederiksen, E V Høgdall, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 15, 1993
The post-operative gonadotropin level in post-menopausal women with epithelial ovarian cancerJ Blaakaer, P Bennett, S Micic, et al.
European Journal of Gynaecological Oncology|April 20, 2006
Improved survival of patients with ovarian cancer in Northern Denmark, 1985-2004M S Tetsche, M Nørgaard, J Jacobsen, et al.
Acta Endocrinologica|August 1, 1992
The pituitary-gonadal axis in women with benign or malignant ovarian tumorsJ Blaakaer, H Djursing, U Hørding, et al.
Gynecologic Oncology|March 6, 2009
Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumorsF D Begum, E Høgdall, S K Kjaer, et al.
Cancer Causes & Control : CCC|October 1, 2013
Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancerM T Faber, A Jensen, K Frederiksen, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 1, 1994
Sex hormone binding globulin phenotypes: their detection and distribution in healthy adults and in different clinical conditionsM M Cornelisse, P E Bennett, M Christiansen, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 15, 1993
Immunoreactive inhibin-production in post-menopausal women with malignant epithelial ovarian tumorsJ Blaakaer, S Micic, I D Morris, et al.
Endocrine-Related Cancer|December 3, 2005
Increased risk of ovarian cancer in integrin beta3 Leu33Pro homozygotesS E Bojesen, S K Kjaer, E V S Høgdall, et al.
Genitourinary Medicine|April 1, 1996
Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital wartsD K Armstrong, R D Maw, W W Dinsmore, et al.
Pageof 4